SZYMON HYZAK: Open Payments
NPI 1083810378 · MERRICK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,044 in 50 payments from 8 companies in 2025. Trend: 2023 $216 · 2024 $304 · 2025 $1,044
Food & beverage: $1,044
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $286 |
| E.R. Squibb & Sons, L.L.C. | 12 | $217 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $179 |
| Vanda Pharmaceuticals Inc. | 3 | $85 |
| Janssen Pharmaceuticals, Inc | 3 | $84 |
| Axsome Therapeutics, Inc. | 4 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
Products named: VRAYLAR, COBENFY, CAPLYTA, FANAPT, SPRAVATO, Auvelity, REXULTI, TRINTELLIX.
Industry payments across NY — which companies pay providers there.
